MODERN APPLICATION OF BETA-ADRENOBLOCKER IN PHARMACOTHERAPY OF CHRONIC HEART FAILURE AMONG PATIENTS WITH ISCHEMIC HEART DISEASE
| Main Author: | Irina V. Askari, Ksenia G. Plaksina, Larisa V. Shekhovtsova, Evgeniy A. Shabanov, Ekaterina V. Dobromirova |
|---|---|
| Format: | Article Journal |
| Bahasa: | eng |
| Terbitan: |
, 2018
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/1490477 |
Daftar Isi:
- Beta-blockers (β-blockers) are among the recommended group of drugs for the treatment of chronic heart failure (CHF) and coronary heart disease. According to the results of clinical trials and meta-analyzes the long-term use of β-blockers improves the outcome of patients with CHF, reduces the risk of cardiovascular events and sudden cardiac death. During an β-blocker selection among CHF patients, it is necessary to evaluate all risk factors, as well as the individual characteristics of the considered drugs. The article highlights the issues the third-generation β-blocker "Nebivolol" modern application. They presented information about the mechanisms of action, the pharmacological profile and the cardioprotective properties of "Nebivolol" for the prevention of myocardial damage after ischemia-reperfusion and myocardial revascularization. The review presents the clinical study data concerning the effect of "Nebivolol" on LV diastolic dysfunction among CHF patients with with a preserved ejection fraction. Key words: Beta-blockers (β-blockers), chronic heart failure (CHF), nebivolol, nitric oxide (NO), myocardial revascularization.